Premium
Unfractionated heparin using actual body weight without dose capping in obese pediatric patients—Subgroup analysis from an observational cohort study
Author(s) -
Kuhn Alexis K.,
Saini Surbhi,
Stanek Joseph,
Dunn Amy,
Kumar Riten
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28872
Subject(s) - medicine , dosing , body mass index , observational study , body weight , cohort , cohort study , heparin , subgroup analysis , therapeutic index , prospective cohort study , pharmacology , confidence interval , drug
To evaluate the correlation between an uncapped, actual body weight‐based unfractionated heparin dosing strategy, we performed a body mass index‐based subanalysis of a previously reported pediatric cohort. Nearly half (45%) of obese patients were supra‐therapeutic on initial anti‐FXa assessment. Obese patients achieved therapeutic anti‐FXa significantly faster than nonobese patients (median 4 vs 12 hours, P = .0192) and were more likely to have any supra‐therapeutic anti‐FXa levels (77% vs 35%; P = .0021). There was no statistically significant difference in major or clinically relevant nonmajor bleeding rates between weight categories ( P = .69). Prospective pediatric studies are warranted to confirm our findings.